NCT05034770

Effectiveness of Major Ozone Autohemotherapy in the Treatment of Fibromyalgia Syndrome

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 45 (actual)
• Sponsor: Emine Dundar Ahi, MD · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Patients who were admitted to the Physical Medicine and Rehabilitation (PMR) outpatient clinic of our hospital between January 2017 and December 2020 and were treated with Major ozone autohemotherapy with a diagnosis of Fibromyalgia syndrome will include to the study. Visual anolog scale (VAS), Fibromyalgia Impact Questionnare (FIQ) and Short Form Health Survey-36 (SF-36) scores of the patients before and after treatment were recorded. Statistical analysis of these outcome scores will be made.

Conditions

• Fibromyalgia Syndrome

Interventions

Type	Name	Description
OTHER	major ozone autohemotherapy	This treatment is based on treating 100 ml of the pa- tient's blood with 100 ml of O3 followed by reinfusion in the donor, in a fast procedure. Each patient received 10 sessions of autohemotherapy with O3 twice a week.

Timeline

• Start date: 2017-01-01
• Primary completion: 2022-01-10
• Completion: 2022-01-11
• First posted: 2021-09-05
• Last updated: 2022-08-05

Locations

1 site across 1 country: Turkey (Türkiye)